In vitro chemosensitivity test to predict chemosensicivity for paclitaxel, using human gastric carcinoma tissues.

使用人胃癌组织进行体外化学敏感性试验，预测紫杉醇的化学敏感性。

• 批准号: 16209041
• 负责人: TANIGAWA Nobuhiko
• 金额: $ 30.95万
• 依托单位: Osaka Medical College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (A)
• 财政年份: 2004
• 资助国家: 日本
• 起止时间: 2004 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-16209041/
• 关键词: anti-cancer agent; chemosensitivity testing; gastric caner; adjuvant chemotherapy; clinical trial; advanced medicine; Japan Research Society for Appropriate Cancer Chem; Japan Clinical Cancer Research Organization; 高度先進医療; 日本がん臨床研究推進機構; 胃癌術後補助化学

In order to evaluate the clinical, usefulness of in vitro chemosensitivity assays for adjuvant chemotherapy for locally advanced gastric cancer, this research group members regularly convene to have discussion to launch up the multi-institutional randomized clinical trial. As one of results, Japan Clinical Cancer Research Organization (JCCRO) involving 36 surgical institutions that scatter nation-wide has agreed to start a new phase II clinical study in which each of patients undergoes postoperative adjuvant chemotherapy with TS-1, oral fluorouridine, would provide any survival advantage for patients with in vitro sensitivity to 5-FU locally advanced gastric cancer. In vitro chemosensitivity is assessed by a CDDST method. The primary endpoint is relapse free aurvival at 3 years after surgery, and the secondary endpoints are overall survival (OS) and to identify whether the patients with in vitro higher response to 5-FU would have better OS than those with in vitro lower response to 5-FU. Patient accrual started on 21st July, 2005, Patients' registry will finish until June, 2009.

为评价体外药敏试验在局部晚期胃癌辅助化疗中的临床实用性，本课题组成员定期召开会议讨论开展多机构随机临床试验。作为结果之一，日本临床癌症研究组织（JCCRO），涉及36个外科机构，分散在全国各地已同意开始一项新的II期临床研究，其中每个患者接受术后辅助化疗TS-1，口服氟尿苷，将提供任何生存优势的患者在体外敏感性5-FU局部晚期胃癌。通过CDDST方法评估体外化疗敏感性。主要终点是术后3年的无复发生存期，次要终点是总生存期（OS），并确定体外对5-FU有较高应答的患者的OS是否优于体外对5-FU有较低应答的患者。患者招募于2005年7月21日开始，患者登记将于2009年6月结束。

项目成果

Gene expression proffle of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouraciFbased chemotherapy.

原发性结直肠癌中 5-氟尿嘧啶代谢酶的基因表达谱：作为基于氟尿嘧啶的化疗反应的预测参数的潜力。

• 发表时间: 2007
• 期刊: Anticancer Res. 27(2)
• 作者: 小伏寛枝;辻典明;今中雄一;Kinoshita M
• 通讯作者: Kinoshita M

高度先進医療 医科(診断) 抗癌剤感受性試験

尖端医学（诊断） 抗癌药物药敏试验

• 发表时间: 2005
• 期刊: からだの科学 増刊巻高度先進医療号
• 作者: 野村栄治;馬渕秀明;谷川允彦
• 通讯作者: 谷川允彦

Combination Therapy of a Novel Oral Fluorouracil Derivative TSI with Low-Dose Cisplatin for Recurrent and Very Advanced Gastric Cancer.

新型口服氟尿嘧啶衍生物 TSI 与低剂量顺铂联合治疗复发性和极晚期胃癌。

• 发表时间: 2004
• 期刊: Jpn J Cancer Chemother. 31(12)
• 作者: F.A. Nae;et. al.;Nakata B
• 通讯作者: Nakata B

A Case of Gastric Cancer with Peritoneal Recurrence Which Developed During Adjuvant Administration of TS-1 Showing Complete Response by Weekly Docetaxel Regimen.

一例在 TS-1 辅助给药期间出现腹膜复发的胃癌病例，每周多西紫杉醇治疗方案显示出完全缓解。

• 发表时间: 2005
• 期刊: Jpn J Cancer Chemother. 32(7)
• 作者: Matsuzaki;J;et al.;Dulundu E;今中 雄一;Takashirna T
• 通讯作者: Takashirna T

TS-1を含む胃癌の多剤併用療法再発・進行胃癌に対するTS-1+低用量CDDP併用療法

胃癌多药联合治疗包括TS-1 TS-1+小剂量CDDP联合治疗复发/晚期胃癌

• 发表时间: 2004
• 期刊: 癌と化学療法 31(12)
• 作者: Ono I;Hamada H et al.;仲田 文造
• 通讯作者: 仲田 文造